CA2684265A1 - Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment - Google Patents

Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment Download PDF

Info

Publication number
CA2684265A1
CA2684265A1 CA002684265A CA2684265A CA2684265A1 CA 2684265 A1 CA2684265 A1 CA 2684265A1 CA 002684265 A CA002684265 A CA 002684265A CA 2684265 A CA2684265 A CA 2684265A CA 2684265 A1 CA2684265 A1 CA 2684265A1
Authority
CA
Canada
Prior art keywords
neu
immunoassay
cells
cancer cells
lysates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002684265A
Other languages
English (en)
French (fr)
Inventor
Robert M. Lorence
Ming Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Biologics Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2684265A1 publication Critical patent/CA2684265A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002684265A 2007-04-19 2008-04-15 Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment Abandoned CA2684265A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91283307P 2007-04-19 2007-04-19
US60/912,833 2007-04-19
PCT/US2008/060317 WO2008130910A1 (en) 2007-04-19 2008-04-15 Detection her-2/neu protein from non-isolated circulating cancer cells and treatment

Publications (1)

Publication Number Publication Date
CA2684265A1 true CA2684265A1 (en) 2008-10-30

Family

ID=39875858

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002684265A Abandoned CA2684265A1 (en) 2007-04-19 2008-04-15 Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment

Country Status (7)

Country Link
US (1) US20100120072A1 (https=)
EP (1) EP2145188A4 (https=)
JP (1) JP2010525326A (https=)
CN (1) CN101663584A (https=)
CA (1) CA2684265A1 (https=)
MX (1) MX2009011228A (https=)
WO (1) WO2008130910A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2364495T3 (es) 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
JP2009514870A (ja) 2005-11-04 2009-04-09 ワイス ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN105147713A (zh) 2008-08-04 2015-12-16 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
SG174382A1 (en) 2009-04-06 2011-11-28 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
CN114805583A (zh) 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体
JP6082344B2 (ja) 2010-05-27 2017-02-15 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
CA2832389A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
CN104122394A (zh) * 2013-04-23 2014-10-29 北京豪迈生物工程有限公司 人表皮生长因子受体2(Her-2)定量测定试剂盒及其检测方法
JP6245147B2 (ja) * 2014-11-19 2017-12-13 株式会社オートネットワーク技術研究所 モールド部付電線
CN104568923A (zh) * 2014-12-01 2015-04-29 浙江省肿瘤医院 电化学发光检测外周血循环肿瘤细胞抗原的方法及试剂盒
JP6323317B2 (ja) * 2014-12-09 2018-05-16 株式会社オートネットワーク技術研究所 端子付電線

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451225B1 (en) * 1986-04-30 2002-09-17 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US6448091B1 (en) * 1988-11-03 2002-09-10 Igen International, Inc. Method and apparatus for improved luminescence assays using particle concentration chemiluminescence detection
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
NO180658C (no) * 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner
US5981203A (en) * 1994-04-26 1999-11-09 The Regents Of The University Of Michigan Unitary sandwich enzyme immunoassay cassette, device and method of use
US5744367A (en) * 1994-11-10 1998-04-28 Igen International, Inc. Magnetic particle based electrochemiluminescent detection apparatus and method
US6884357B2 (en) * 1995-02-21 2005-04-26 Iqbal Waheed Siddiqi Apparatus and method for processing magnetic particles
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
DE69637001T2 (de) * 1995-06-07 2007-12-06 Bioveris Corp. Elektrochemilumineszenz-enzymimmunoassay
US6117985A (en) * 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
US6190870B1 (en) * 1995-08-28 2001-02-20 Amcell Corporation Efficient enrichment and detection of disseminated tumor cells
US6297062B1 (en) * 1996-03-07 2001-10-02 Bio-Magnetics Ltd. Separation by magnetic particles
US6890426B2 (en) * 1996-06-07 2005-05-10 Immunivest Corporation Magnetic separation apparatus and methods
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO1999041613A1 (en) * 1998-02-12 1999-08-19 Immunivest Methods and reagents for the rapid and efficient isolation of circulating cancer cells
AU2876900A (en) * 1999-02-10 2000-08-29 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids andmethods of use
US6300143B1 (en) * 1999-03-01 2001-10-09 Idec Pharmaceuticals Corporation Electrochemiluminescent assays for eukaryotic cells
US6969615B2 (en) * 1999-07-26 2005-11-29 20/20 Genesystems, Inc. Methods, devices, arrays and kits for detecting and analyzing biomolecules
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
JP3313107B2 (ja) * 2001-03-22 2002-08-12 バイエル コーポレイション ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量
DE10143776A1 (de) * 2001-09-06 2003-04-03 Adnagen Ag Verfahren und Kit zur Diagnostik oder Behandlungskontrolle von Brustkrebs
DE60237531D1 (de) * 2001-10-11 2010-10-14 Aviva Biosciences Corp Verfahren zum trennen von seltenen zellen von fluidproben
EP1597353B1 (en) * 2003-02-27 2010-11-24 Veridex, LLC CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS
CA2582713A1 (en) * 2004-10-06 2006-04-20 Wellstat Biologics Corporation Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
EP1816477A1 (en) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG The use of natriuretic peptides and placenta growth factor levels for risk stratification of individuals elected for cardiac stress testing
MX2008013331A (es) * 2006-04-18 2008-11-10 Wellstat Biologics Corp Deteccion de receptores de esteroides en celulas de carcinoma circulantes y tratamiento.
EP2008102A4 (en) * 2006-04-18 2009-07-08 Wellstat Biologics Corp DETECTION OF PROTEINS IN NEOPLASTIC CELLS IN CIRCULATION
US8557531B2 (en) * 2006-04-18 2013-10-15 Wellstat Biologics Corporation Detection of circulating endothelial cells

Also Published As

Publication number Publication date
MX2009011228A (es) 2009-11-02
EP2145188A4 (en) 2010-06-30
US20100120072A1 (en) 2010-05-13
JP2010525326A (ja) 2010-07-22
CN101663584A (zh) 2010-03-03
EP2145188A1 (en) 2010-01-20
WO2008130910A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
US20100120072A1 (en) Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment
JP4798801B2 (ja) 循環する癌細胞におけるＨｅｒ−２／ｎｅｕタンパク質のレベルの上昇の検出および処置
JP2010525326A5 (https=)
Panigrahi et al. Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients
Cao et al. Plasma soluble HLA‐G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer
US8012480B2 (en) Detection of proteins from circulating neoplastic cells
Theodoraki et al. Clinical significance of PD-L1+ exosomes in plasma of head and neck cancer patients
Catenacci et al. Acquisition of portal venous circulating tumor cells from patients with pancreaticobiliary cancers by endoscopic ultrasound
JP5078100B2 (ja) 循環癌細胞におけるステロイド受容体の検出および処置
Yabuki et al. Immunohistochemical study of DNA topoisomerase II in human gastric disorders
KR102372697B1 (ko) 간외 담관암, 간내 담관암, 또는 담낭암의 진단용 바이오 마커
EP0336677B1 (en) A method for early detection of lung cancer
Borgen et al. A European interlaboratory testing of three well‐known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow
Japink et al. CEA in activated macrophages. New diagnostic possibilities for tumor markers in early colorectal cancer
EP2008103A2 (en) Detection of circulating endothelial cells
RU2745060C2 (ru) Биомаркеры для комбинированной терапии, включающей ленватиниб и эверолимус
JP2021531816A (ja) 骨髄系由来サプレッサー細胞亜集団の検出および単離
Ulvang et al. Co-expression of tissue factor, TROP2, and NECTIN4 in primary and matched metastatic cervical cancer lesions
Kakurina et al. The serum fascin-1 and tumor components containing this protein in patients with head and neck squamous cell carcinoma: A pilot study
HK1103439B (en) Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140415